The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Syros Pharmaceuticals Inc. shares valued at $85,420 were purchased by Chee Conley on Sep 11 ’24. At $1.71 per share, Chee Conley acquired 50,000 shares. The insider’s holdings grew to 122,504 shares worth approximately $0.25 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Haas Jason purchased 45,344 shares, netting a total of over 76,006 in proceeds. Following the buying of shares at $1.68 each, the insider now holds 124,552 shares.
Before that, Chee Conley had added 50,000 shares to its account. In a trade valued at $75,260, the President & CEO bought Syros Pharmaceuticals Inc. shares for $1.51 each. Upon closing the transaction, the insider’s holdings increased to 50,000 shares, worth approximately $0.15 million.
As published in a research note from H.C. Wainwright on November 04, 2020, Syros Pharmaceuticals Inc. [SYRS] has been rated up from a Neutral to a Buy and the price target has been revised to $15 from $11. Analysts at Alliance Global Partners started covering the stock with ‘”a Buy”‘ outlook in a report released in late September. As of January 17, 2020, Wedbush has decreased its “an Outperform” rating to a “Neutral” for SYRS.
Analyzing SYRS Stock Performance
During the last five days, there has been a surge of approximately 6.15%. Over the course of the year, Syros Pharmaceuticals Inc. shares have dropped approximately -73.43%. Shares of the company reached a 52-week high of $8.17 on 01/02/24 and a 52-week low of $1.43 on 09/10/24. A 50-day SMA is recorded $1.84, while a 200-day SMA reached $4.88. Nevertheless, trading volume fell to 0.73 million shares from 1.27 million shares the previous day.
Support And Resistance Levels for Syros Pharmaceuticals Inc. (SYRS)
According to the 24-hour chart, there is a support level at 1.94, which, if violated, would cause prices to drop to 1.81. In the upper region, resistance lies at 2.28. The next price resistance is at 2.49. RSI (Relative Strength Index) is 49.69 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.22, which suggests the price will decrease in the coming days. Percent R is at 71.31%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
